Back to Market Feed

This NDC is on FDA's drug shortage list (posted Oct 14, 2016)

Product Information

XYLOCAINE 2%-EPI 1:100,000 is a brand product labeled by Fresenius Kabi USA, LLC, priced at $0.2655 per ML under NDC 63323048327. Its NADAC has been published 69 times since Oct 23, 2024.

FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.

XYLOCAINE 2%-EPI 1:100,000

LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE
$0.2655per ML

Strength

.01; 20 mg/mL; mg/mL

NDC

63323048327

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

INFILTRATION; PERINEURAL

Effective Date

2/1/2025

Approval Type

New Drug (NDA)

FDA Application

NDA006488

FDA Approved

Before 1982

TE Code

AP

On Market Since

8/12/2010

Pharmacological Classes

Adrenergic alpha-Agonists
Adrenergic beta-Agonists
Amide Local Anesthetic
Amides
Antiarrhythmic
Catecholamine
Catecholamines
Local Anesthesia
alpha-Adrenergic Agonist
beta-Adrenergic Agonist

Price Statistics

The NADAC for XYLOCAINE 2%-EPI 1:100,000 has been published 69 times since Oct 23, 2024, and over the history we have for it it has risen 18.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2655 per ML
All-time high$0.2655 (Feb 11, 2026)
All-time low$0.2222 (Nov 20, 2024)
52-week high$0.2655
52-week low$0.2655
Median price$0.2655
Average price$0.2567
Largest weekly change+14.1% (Feb 12, 2025)
Weeks tracked69
Tracking sinceOct 23, 2024

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

0.0%

3Y

N/A

5Y

N/A

All

+18.2%

Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

NINJACOF-D LIQUID
Brand
23359003416•Centurion Labs, LLC
$0.0825
per ML
MARCAINE 0.5% VIAL
Brand
00409161050•Hospira Inc.
$0.0977
per ML
SENSORCAINE 0.5% VIAL
Brand
63323046757•Fresenius Kabi USA, LLC
$0.0977
per ML
VANACOF LIQUID
Brand
58809099901•GM Pharmaceuticals, INC
$0.1051
per ML
SILVADENE 1% CREAM
Brand
61570013140•Pfizer Inc.
$0.1247
per GM
SILVADENE 1% CREAM
Brand
61570013150•Pfizer Inc.
$0.2447
per GM
SILVADENE 1% CREAM
Brand
61570013155•Pfizer Inc.
$0.2447
per GM
ADVIL COLD & SINUS CAPLET
Brand
00573018010•Haleon US Holdings LLC
$0.2615
per EA
ADVIL COLD & SINUS CAPLET
Brand
00573018021•Haleon US Holdings LLC
$0.2615
per EA
SILVADENE 1% CREAM
Brand
61570013185•Pfizer Inc.
$0.2732
per GM

Frequently asked questions

What is the NADAC price of XYLOCAINE 2%-EPI 1:100,000?

The current National Average Drug Acquisition Cost (NADAC) for XYLOCAINE 2%-EPI 1:100,000, manufactured by Fresenius Kabi USA, LLC, is $0.2655 per ML (NDC 63323048327), effective Feb 11, 2026.

How has the price of XYLOCAINE 2%-EPI 1:100,000 changed over time?

Over the history we have for it, the NADAC for XYLOCAINE 2%-EPI 1:100,000 has risen 18.2%. It has been tracked across 69 weekly CMS publications since Oct 23, 2024.

What are the highest and lowest recorded NADAC prices for XYLOCAINE 2%-EPI 1:100,000?

Since Oct 23, 2024, the NADAC for XYLOCAINE 2%-EPI 1:100,000 has ranged from a low of $0.2222 (Nov 20, 2024) to a high of $0.2655 (Feb 11, 2026), with a median of $0.2655 per ML.

Are there cheaper alternatives to XYLOCAINE 2%-EPI 1:100,000?

No other NADAC-published product currently shares the active ingredient and strength of XYLOCAINE 2%-EPI 1:100,000 in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures XYLOCAINE 2%-EPI 1:100,000?

XYLOCAINE 2%-EPI 1:100,000 (NDC 63323048327) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a brand product.

Is XYLOCAINE 2%-EPI 1:100,000 in shortage?

Yes — NDC 63323048327 is currently listed in FDA's drug shortage database (posted Oct 14, 2016).